111 results
Page 2 of 6
8-K
EX-99.1
4rj ttm81
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
EX-99.1
uamlz7rkxh695u ns
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am
8-K
EX-99.1
tc51 h951
24 Oct 23
Regulation FD Disclosure
4:30pm
8-K
j9b01qr fea20
15 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-99.1
cc9hmjk
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
8-K
EX-4.2
g9hh3vbzxed7yx25 lul
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
8-K
EX-10.2
nr3ire
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
8-K
EX-10.1
en8s25z
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-99.2
bjrzmd7b
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-99.1
4w59sov
24 Oct 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
9:41am
8-K
np1g 1irt01
6 Apr 22
Bio-Path Holdings Appoints Aline Sherwood to Board of Directors
4:30pm
8-K
EX-99.1
gzzz wkz3
11 Mar 22
Bio-path Holdings Reports Full Year 2021 Financial Results
7:30am
8-K
bop 1dkhylut
25 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-99.1
mz0rso0ggvlhm7uy9s8l
13 Dec 21
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
7:40am